AbilityPharma Raising Venture Capital
AbilityPharma Raises €7M in Funding
Key Highlights:
- Funding Round: AbilityPharma, a biopharmaceutical company focused on oral autophagy-inducing anticancer compounds, raised €7M in funding.
- Investors: CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent, and CDTI Innvierte participated in the funding round.
- Phase 2b Clinical Study: The funds will be used to finance a phase 2b clinical study of ABTL0812, an antitumor compound, in patients with pancreatic cancer.
AbilityPharma's Target Market
- Target Market: Patients with pancreatic cancer, specifically those in need of innovative oral autophagy-inducing anticancer compounds.
- Medical Professionals and Researchers: Oncologists, clinical trial investigators, and researchers in the field of pancreatic cancer treatment.
- Pharmaceutical Companies and Investors: Companies and investors interested in supporting the development of innovative cancer treatments.
What AbilityPharma Needs to Buy
- Clinical Research Services: Collaborations with research organizations and hospitals for conducting clinical trials and gathering efficacy data.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers to ensure the production and distribution of their anticancer compounds.
- Marketing and Awareness Campaigns: Services to raise awareness about their innovative oral autophagy-inducing anticancer compounds among medical professionals and patients.